Medtronic Launches Resolute Integrity DES in Europe

August 30, 2010 — Medtronic, Inc. (Minneapolis, MN) announced the receipt of CE mark approval for the Resolute Integrity drug-eluting stent (DES) system for the treatment of coronary artery disease. The company has launched the device in European and other countries outside the United States that recognize the CE mark.

According to Medtronic, the Resolute Integrity features a drug-eluting coronary stent with superior deliverability. The device design is based on continuous sinusoid technology that,  coupled with Medtronic's MicroTrac delivery system, improves deliverability without compromising other important stent design characteristics, such as radial strength, and it improves the stent's conformability. The Resolute Integrity DES combines this technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer, said Medtronic.

“Medtronic stents built on continuous sinusoid technology are noticeably more deliverable, giving me greater confidence that I can reach the target lesion, even in patients with especially tortuous anatomy or narrow vessels,” commented Neal Uren, MD. “It's a significant innovation for the clinical practice of interventional cardiology that sets a new gold standard for deliverability.”